Artiva Biotherapeutics (ARTV) CEO Aslan Fred Sells 61,888 Shares

What Happened

• Aslan Fred, CEO of Artiva Biotherapeutics (ARTV), disposed of 61,888 shares on 2026-09-03 in a sale reported on Form 4. The transaction generated $690,392 in proceeds. The filing indicates this was a sell-to-cover transaction to satisfy tax withholding on vested restricted stock units (i.e., routine disposition rather than a discretionary sale).

Key Details

• Transaction date: 2026-09-03; filing date: 2026-09-04 (timely).
• Transaction type/code: Sale (S) — reported as open market or private sale; described as automatic sell-to-cover to cover tax withholding (Footnote F1).
• Price details: weighted average sale price $11.1555; price range $11.0270–$11.1556 (Footnote F2). Full per-price breakdown available on request.
• Shares disposed: 61,888; proceeds reported $690,392.
• Shares owned after transaction: not stated in the excerpt of the filing provided.
• Filing timeliness: appears timely (filed the day after the transaction).

Context

• The filing’s footnote clarifies the sale was automatic to cover tax obligations tied to RSU vesting, which is common and usually not read as a signal of management’s view on the company. No 10b5-1 plan or other trading plan was referenced in the provided excerpt.